Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.



Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis

Author affiliations

Abstract

Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the development of atherosclerosis. However, the application of bindarit (a specific synthetic inhibitor of MCP-1) in atherosclerosis has not been confirmed due to the non-specific distribution profile in vivo. Herein, based on the recruitment of monocytes into atherosclerotic plaques, we successfully delivered bindarit into the interior of atherosclerotic plaques through a yeast-derived microcapsule (YC) mediated biomimetic approach. In this biomimetic approach, bindarit was firstly assembled with polyethyleneimine to form the positively charged nanoparticles (BIN/PEI NPs) via multiple intermolecular forces, and then the obtained BIN/PEI NPs were packed into YCs by electrostatic force-mediated spontaneous deposition. Through an oral adsorption routine similar to yeasts, bindarit loaded YCs (BIN/YCs) were distributed into peripheral blood monocytes after oral administration, and then their targeted delivery to atherosclerotic plaques was successfully performed through monocyte transportation. Correspondingly, oral delivery of bindarit loaded YCs afforded notably potentiated efficacies for inhibiting the MCP-1 and further reducing the recruitment of monocytes into atherosclerotic plaques, and thus presented a good efficacy in preventing the formation of atherosclerotic plaques. These results demonstrated that a ‘Trojan horse’-like YC mediated nanomedicine delivery strategy is expected to realize the application of certain potential anti-inflammatory drugs in the treatment of atherosclerosis and is of great significance for the development of novel strategies for atherosclerosis treatment.

Graphical abstract: Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis

Back to tab navigation

Supplementary files

Article information


Submitted
14 Mar 2020
Accepted
06 May 2020
First published
07 May 2020

Biomater. Sci., 2020, Advance Article
Article type
Paper

Biomimetic oral targeted delivery of bindarit for immunotherapy of atherosclerosis

L. Yin, C. Peng, Y. Tang, Y. Yuan, J. Liu, T. Xiang, F. Liu, X. Zhou and X. Li, Biomater. Sci., 2020, Advance Article , DOI: 10.1039/D0BM00418A

Social activity

Search articles by author

Spotlight

Advertisements